<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/43DBCE3E-240B-4A6A-9BF0-DE2D811C7436"><gtr:id>43DBCE3E-240B-4A6A-9BF0-DE2D811C7436</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Koltzenburg</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802497"><gtr:id>D5D9C377-526F-4093-B983-5B38046EEFBC</gtr:id><gtr:title>Investigating the target engagement of ion channels in human peripheral nerve by drugs</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802497</gtr:grantReference><gtr:abstractText>Ion channels are proteins in nerves cells that control their excitability and information transmission. Several lines of evidence indicate that novel drugs that modulate these ion channels could work as potent pain killers. So far it has been impossible to non-invasively study the action of drugs on these ion channels in humans and this has hampered the transition from preclinical studies on animals to early clinical trials in humans volunteers. This proposed research project aims to develop a platform technology that would eliminate this bottleneck. It uses a semi-automated computer system that administers small, painless electrical impulses in different configurations to a nerve of the hand. The responses recorded from muscle or a finger inform us about the activity of various ion channels in motor or sensory nerve fibres, respectively. To validate the method we are interested to see whether different drugs that are known to affect specific ion channels evoke distinct changes of ion channels and thereby nerve responses that we can pick up with the new technique. This information is important for several critical steps of drug discovery programs. First, it allows to see whether drug effects are specific. Second, one can also see what percentage of ion channels are affected at a given dose. This will facilitate the crucial step of appropriate dose finding when drugs move from animal studies to human investigations. Furthermore, it is not uncommon that animal studies suggest pain relieving effects, whereas the same compound appears to have no such effect in patients. This can happen because the drug is not effectively modulating the ion channel in humans or, alternatively, the ion channel is modulated, but the ion channel is not important for pain perception in humans. This puzzle can only be answered by direct measurement of the drug effect on the ion channel ? or to say it in the words of an engineer ? to measure is to know. This is currently not possible, but the technology we wish to develop, holds the promise to this for the first time.</gtr:abstractText><gtr:technicalSummary>Increases in peripheral nerve excitability are the cause of many forms of pain. Drugs modulating ion channels in peripheral nerve are therefore a prime target for novel analgesics. However, a major bottleneck in drug discovery for these compounds is the lack of translational biomarkers. The proposed project will employ the techniques of nerve excitability testing that is used in animal models in vivo and in vitro and that can be applied to humans to human volunteers and patients. The aim is to conduct a series of proof of concept studies in order to establish this technique as the first translational biomarker for ion channel function in clinical trial programs including dose finding studies. We will use available reference compounds lamotrigine, lacosamide, ivabradine or retigabine in normal volunteers to modulate sodium or potassium channels or the Ih current, respectively to see whether this technique affects distinct nerve excitability parameters. After successful completion this project is likely to sustain its future funding through pharmacutical companies developing novel ion channel modulators</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>235876</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neusentis Pfizer</gtr:department><gtr:description>Neusentis</gtr:description><gtr:id>B5410B9D-49B1-413B-A66F-1C55E0B70CE2</gtr:id><gtr:impact>Currently studying drugs</gtr:impact><gtr:outcomeId>sg4NedzEWcw-1</gtr:outcomeId><gtr:partnerContribution>Collaborating on early clinical and preclinical development of novel analgesic drugs that atrget voltage gated sodium channels and neurotrophins</gtr:partnerContribution><gtr:piContribution>UK drug company</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Drug Disovery Fund</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>52C3A21F-6A93-4122-A1FF-B12AD477BF42</gtr:id><gtr:outcomeId>RBqjczNK9Ud0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>88337423-1B57-4160-8F17-529FFEA2D673</gtr:id><gtr:outcomeId>G7FofyGHZoE</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Development of a translational neurophysiological biomarker for the assessment of the target engagement of ion channels by drugs.</gtr:description><gtr:id>9A75A425-F52B-4786-A970-A027AB9A0F61</gtr:id><gtr:impact>Better translation from pre-clinical to early clinical trials</gtr:impact><gtr:outcomeId>qRFn9fVgKpX</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>QTRAC CBZ</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=9799</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>In collaboration with Erik Arstad we have analysed novel sodium channel antagonists using several in vitro nerve excitability parameters</gtr:description><gtr:id>90F6A04E-E7BE-42A7-9DCF-18EA8916233E</gtr:id><gtr:impact>This work has just been started</gtr:impact><gtr:outcomeId>UrNaRqrmNhQ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Analysis of novel sodium channel antagonists</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4A5BBD86-9E55-4D84-8A9F-016C33681CE5</gtr:id><gtr:title>Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ba5296e6952b631a1ef1bd99983f6a2"><gtr:id>0ba5296e6952b631a1ef1bd99983f6a2</gtr:id><gtr:otherNames>Raftopoulos R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56e0aae49b8889.06704265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>711EB319-433A-42E3-8C38-27A0C00BB5C9</gtr:id><gtr:title>Is overwork weakness relevant in Charcot-Marie-Tooth disease?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5523874169f71a476541373c881cf885"><gtr:id>5523874169f71a476541373c881cf885</gtr:id><gtr:otherNames>Piscosquito G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5464ae745fc8d3.99442156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0A0C897-6533-483A-A7BC-65AE03656E9D</gtr:id><gtr:title>Chemotherapy-induced peripheral neurotoxicity: A critical analysis.</gtr:title><gtr:parentPublicationTitle>CA: a cancer journal for clinicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9e06be21bb19cb63cdc94aab4673f50"><gtr:id>e9e06be21bb19cb63cdc94aab4673f50</gtr:id><gtr:otherNames>Park Susanna B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15004_24_24178709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF4B0906-4512-4BEF-A212-AB616032E84A</gtr:id><gtr:title>Pain and small fiber function in Charcot-Marie-Tooth disease type 1A.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/864491faea7bd8b373d3e523061dadf8"><gtr:id>864491faea7bd8b373d3e523061dadf8</gtr:id><gtr:otherNames>Laur? M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>5464ae74149a45.67009967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D25F687-89A4-4E69-BA78-A59094AE6B99</gtr:id><gtr:title>c-Jun activation in Schwann cells protects against loss of sensory axons in inherited neuropathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1574edb84a7851655633107e56643146"><gtr:id>1574edb84a7851655633107e56643146</gtr:id><gtr:otherNames>Hantke J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5464ae748868c1.04491422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F3E21B8-0894-4D7C-B768-C45AFCD02416</gtr:id><gtr:title>Longitudinal assessment of oxaliplatin-induced neuropathy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad96dacc5fb7c144fb8571a7ed6cdcf0"><gtr:id>ad96dacc5fb7c144fb8571a7ed6cdcf0</gtr:id><gtr:otherNames>Park SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_15004_24_22232054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>657FB805-6332-4962-AE65-4F4A4AD193E6</gtr:id><gtr:title>Functional imaging in microfluidic chambers reveal sensory neuron sensitivity is differentially regulated between neuronal regions.</gtr:title><gtr:parentPublicationTitle>Pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1cc2aa8d2d6d1ed6ad73bf575ba1f1f"><gtr:id>f1cc2aa8d2d6d1ed6ad73bf575ba1f1f</gtr:id><gtr:otherNames>Clark AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0304-3959</gtr:issn><gtr:outcomeId>5aa9c00fbfd256.97292613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82D80A4B-1A55-4D3F-96BF-380DE1494EDB</gtr:id><gtr:title>Chronic immune sensory polyradiculopathy with cranial and peripheral nerve involvement.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f32c4fbc954a0618769c4233e158d0"><gtr:id>f8f32c4fbc954a0618769c4233e158d0</gtr:id><gtr:otherNames>Trip SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5464ae73084c75.71619852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>187DFB88-4CAC-40CF-AF88-BF148A3C9377</gtr:id><gtr:title>Protons regulate the excitability properties of rat myelinated sensory axons in vitro through block of persistent sodium currents.</gtr:title><gtr:parentPublicationTitle>Journal of the peripheral nervous system : JPNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb3d988a976e5e6581ec095aae5ea219"><gtr:id>fb3d988a976e5e6581ec095aae5ea219</gtr:id><gtr:otherNames>Maurer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1085-9489</gtr:issn><gtr:outcomeId>5464ae7333fda6.14614645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53873DF7-DCEB-44AA-B9FC-90B498B01A43</gtr:id><gtr:title>Deletion of chromosome 12q21 affecting KCNC2 and ATXN7L3B in a family with neurodevelopmental delay and ataxia.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5464ae73591df4.57124131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B987CA09-CF72-4AC3-A49D-DD11BAEC8A2B</gtr:id><gtr:title>The Nerve Excitability Profile is a novel biomarker to assess the effect of drugs on voltage gated sodium channels in human peripheral nerve</gtr:title><gtr:parentPublicationTitle>2012 Neuroscience Meeting Planner</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3642cdce70cc57da732d6b6269fc5429"><gtr:id>3642cdce70cc57da732d6b6269fc5429</gtr:id><gtr:otherNames>Molyneux A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>qUKYk8ZNhrP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE434E45-714F-438F-9D79-5441F42AD3D3</gtr:id><gtr:title>A novel prion disease associated with diarrhea and autonomic neuropathy.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5464ae73d5aee9.92275859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09471261-7807-4964-A8DF-80EF29536703</gtr:id><gtr:title>Novel mutations in human and mouse SCN4A implicate AMPK in myotonia and periodic paralysis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae312a95b658688d9e502f838b047b75"><gtr:id>ae312a95b658688d9e502f838b047b75</gtr:id><gtr:otherNames>Corrochano S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5464ae74b13f90.32382071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3466E83D-B176-44F1-B32B-FA1754ED0805</gtr:id><gtr:title>Chemotherapy-induced peripheral neurotoxicity: a critical analysis.</gtr:title><gtr:parentPublicationTitle>CA: a cancer journal for clinicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad96dacc5fb7c144fb8571a7ed6cdcf0"><gtr:id>ad96dacc5fb7c144fb8571a7ed6cdcf0</gtr:id><gtr:otherNames>Park SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-9235</gtr:issn><gtr:outcomeId>5464ae743aef82.01807684</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802497</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>